ID   NEC8
AC   CVCL_1604
SY   NEC-8
DR   BTO; BTO:0006542
DR   CLO; CLO_0051391
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471665
DR   cancercelllines; CVCL_1604
DR   Cell_Model_Passport; SIDM00243
DR   ChEMBL-Cells; CHEMBL3308176
DR   ChEMBL-Targets; CHEMBL2366340
DR   Cosmic; 910942
DR   Cosmic-CLP; 910942
DR   DepMap; ACH-002288
DR   EGA; EGAS00001000978
DR   GDSC; 910942
DR   GEO; GSM827251
DR   GEO; GSM1670276
DR   IARC_TP53; 21583
DR   JCRB; JCRB0250
DR   JCRB; FDSC0005
DR   LINCS_LDP; LCL-1900
DR   PharmacoDB; NEC8_1156_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1604
DR   PubChem_Cell_line; CVCL_1604
DR   RCB; RCB0489
DR   Wikidata; Q54930382
RX   PubMed=520758;
RX   PubMed=2445169;
RX   PubMed=3518877;
RX   PubMed=3618218;
RX   PubMed=9290701;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=2.09%; Native American=0.61%; East Asian, North=79.76%; East Asian, South=13.39%; South Asian=0%; European, North=0%; European, South=4.15% (PubMed=30894373).
CC   Discontinued: JCRB; FDSC0005; true.
CC   Derived from site: In situ; Testis; UBERON=UBERON_0000473.
ST   Source(s): Cosmic-CLP; JCRB; RCB
ST   Amelogenin: X
ST   CSF1PO: 13,15
ST   D13S317: 12
ST   D16S539: 9,10
ST   D5S818: 10,14
ST   D7S820: 8
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 14,15
DI   NCIt; C6341; Testicular embryonal carcinoma
DI   ORDO; Orphanet_289362; Non-central nervous system-localized embryonal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   24Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   PubMed=520758; DOI=10.20772/cancersci1959.70.5_677;
RA   Yamamoto T., Komatsubara S., Suzuki T., Oboshi S.;
RT   "In vitro cultivation of human testicular embryonal carcinoma and
RT   establishment of a new cell line.";
RL   Gann 70:677-680(1979).
//
RX   PubMed=2445169; DOI=10.1111/j.1440-1827.1987.tb00459.x;
RA   Motoyama T., Watanabe H., Yamamoto T., Sekiguchi M.;
RT   "Production of alpha-fetoprotein by human germ cell tumors in vivo and
RT   in vitro.";
RL   Acta Pathol. Jpn. 37:1263-1277(1987).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3618218; DOI=10.1111/j.1440-1827.1987.tb00377.x;
RA   Motoyama T., Watanabe H., Yamamoto T., Sekiguchi M.;
RT   "Human testicular germ cell tumors in vitro and in athymic nude
RT   mice.";
RL   Acta Pathol. Jpn. 37:431-448(1987).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//